The role of dexmedetomidine in ARDS: an approach to non-intensive care sedation

Francesca Simioli; Anna Annunziata; Antonietta Coppola; Pasquale Imitazione; Angela Irene Mirizzi; Antonella Marotta; Rossella D'Angelo; Giuseppe Fiorentino

doi:10.3389/fmed.2023.1224242

The role of dexmedetomidine in ARDS: an approach to non-intensive care sedation

Front Med (Lausanne). 2023 Aug 31:10:1224242. doi: 10.3389/fmed.2023.1224242. eCollection 2023.

Authors

Francesca Simioli¹, Anna Annunziata¹, Antonietta Coppola¹, Pasquale Imitazione¹, Angela Irene Mirizzi¹, Antonella Marotta¹, Rossella D'Angelo¹, Giuseppe Fiorentino¹

Affiliation

¹ Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O. dei Colli, Naples, Italy.

Abstract

Introduction: Severe COVID-19 is a life-threatening condition characterized by complications such as interstitial pneumonia, hypoxic respiratory failure, and acute respiratory distress syndrome (ARDS). Non-pharmacological intervention with mechanical ventilation plays a key role in treating COVID-19-related ARDS but is influenced by a high risk of failure in more severe patients. Dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that provides sedative effects with preservation of respiratory function. The aim of this study is to assess how dexmedetomidine influences gas exchange during non-invasive ventilation (NIV) and high-flow nasal cannula (HFNC) in moderate to severe ARDS caused by COVID-19 in a non-intensive care setting.

Methods: This is a single center retrospective cohort study. We included patients who showed moderate to severe respiratory distress. All included subjects had indication to NIV and were suitable for a non-intensive setting of care. A total of 170 patients were included, divided in a control group (n = 71) and a treatment group (DEX group, n = 99).

Results: A total of 170 patients were hospitalized for moderate to severe ARDS and COVID-19. The median age was 71 years, 29% females. The median Charlson comorbidity index (CCI) was 2.5. Obesity affected 21% of the study population. The median pO₂/FiO₂ was 82 mmHg before treatment. After treatment, the increase of pO₂/FiO₂ ratio was clinically and statistically significant in the DEX group compared to the controls (125 mmHg [97-152] versus 94 mmHg [75-122]; ***p < 0.0001). A significative reduction of NIV duration was observed in DEX group (10 [7-16] days vs. 13 [10-17] days; *p < 0.02). Twenty four patients required IMV in control group (n = 71) and 16 patients in DEX group (n = 99) with a reduction of endotracheal intubation of 62% (OR 0.38; **p < 0.008). A higher incidence of sinus bradycardia was observed in the DEX group.

Conclusion: Dexmedetomidine provides a "calm and arousal" status which allows spontaneous ventilation in awake patients treated with NIV and HFNC. The adjunctive therapy with dexmedetomidine is associated with a higher pO₂/FiO₂, lower duration of NIV, and a lower risk of NIV failure. A higher incidence of sinus bradycardia needs to be considered.

Keywords: COVID-19; acute respiratory distress syndrome; continuous positive airway pressure; high flow nasal cannula; non-invasive ventilation; pressure support ventilation; refractory hypoxemia; respiratory drive.